
    
      To evaluate the efficacy of four dosages of mg DNB-001 administered twice daily (bid) per os
      (p.o.) as an anti-ocular hypertensive agent, compared with placebo administered bid po, for
      28 days, in patients with ocular hypertension.
    
  